Sunshine Heart Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sunshine Heart Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EDEN PRAIRIE, Minn., Oct. 25, 2013 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc.
(Nasdaq:SSH), today announced that on October 21, 2013, the Compensation
Committee of its Board of Directors approved five equity awards under Sunshine
Heart's New-Hire Equity Incentive Plan, as material inducements to five
individuals' entering into employment with the Company. The equity awards were
approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also
requires a public announcement of equity awards that are not made under a
stockholder approved equity plan.

In connection with their entering into employment with Sunshine Heart, the
five individuals, who were not previously employees or directors of Sunshine
Heart, received options to purchase an aggregate of 303,000 shares of the
Company's common stock. Options granted to four of the new hires, for an
aggregate of 268,000 shares, including the option for 148,000 shares granted
to Patrick Verta, Sunshine Heart's newly hired Chief Medical Officer, have an
exercise price of $10.73 per share, which is equal to the closing price of the
Company's common stock on October 21, 2013. One of the options, for 35,000
shares, will be granted effective October 28, 2013, and will have an exercise
price equal to the closing price of the Company's common stock on that date.
All five options have ten-year terms and vest over a period of four years,
with 25% vesting one year after the date of grant and the remaining 75%
vesting in 36 approximately equal monthly increments, provided the new hire's
employment is continuing on each such date, and subject to acceleration or
forfeiture upon the occurrence of certain events as set forth in the new
hire's option agreement.

About Sunshine^® Heart

Sunshine Heart, Inc. is an early-stage medical device company focused on
developing, manufacturing and commercializing the C-Pulse System for treatment
of Class III and ambulatory Class IV heart failure. Sunshine Heart has
completed an approved U.S. Food and Drug Administration (FDA) feasibility
clinical trial of the C-Pulse System and presented the results in
November2011. In March 2012, the FDA notified the Company that it could move
forward with an investigational device exemption (IDE) application. Sunshine
Heart received unconditional approval from the FDA in November2012 to
initiate its pivotal trial. In July2012 Sunshine Heart received CE Mark
approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware
corporation headquartered in Minneapolis with a wholly owned subsidiary in
Australia. The Company has been listed on the NASDAQ Capital Market since

About the C-Pulse^® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device
in the United States, Canada and countries that do not recognize the CE mark
approval, utilizes the scientific principles of intra-aortic balloon
counter-pulsation applied in an extra-aortic approach to assist the left
ventricle by reducing the workload required to pump blood throughout the body,
while increasing blood flow to the coronary arteries. Combined, these
potential benefits may help sustain the patient's current condition or, in
some cases, reverse the heart failure process, thereby potentially preventing
the need for later-stage heart failure devices, such as left ventricular
assist devices (LVADs), artificial hearts or transplants. It may also provide
relief from the symptoms of Class III and ambulatory Class IV heart failure
and improve quality of life and cardiac function. Based on the results from
our feasibility trial, we also believe that some patients treated with our
C-Pulse System will be able to stop using the device due to sustained
improvement in their conditions as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to
Investigational use.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are
based on management's beliefs, assumptions and expectations and information
currently available to management. All statements that address future
operating performance, events or developments that we expect or anticipate
will occur in the future are forward-looking statements, including, without
limitation, our expectations with respect to future clinical trial activities
and results including patient enrollment in trials. These forward-looking
statements are subject to numerous risks and uncertainties, including, without
limitation, the possibility that our clinical trials do not meet their
enrollment goals, meet their end-points or otherwise fail, that regulatory
authorities do not accept our application or approve the marketing of the
C-Pulse System, the possibility that we may be unable to raise the funds
necessary for the development and commercialization of our products, that we
may not be able to commercialize our products successfully in the EU and the
other risk factors described under the caption "Risk Factors" and elsewhere in
our filings with the Securities and Exchange Commission. You should not place
undue reliance on forward-looking statements because they speak only as of the
date when made and may turn out to be inaccurate. We do not assume any
obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. We may not
actually achieve the plans, projections or expectations disclosed in
forward-looking statements, and actual results, developments or events could
differ materially from those disclosed in the forward-looking statements.

         Laura Forman
         Blueprint Life Science Group
         T: +1-415-375-3340
         Jeff Mathiesen
         Chief Financial Officer
         Sunshine Heart, Inc.
         T: +1-952-345-4200

Sunshine Heart logo
Press spacebar to pause and continue. Press esc to stop.